How can real-world evidence (RWE) support health technology assessment (HTA)? Can real-world data (RWD) supplement clinical data? How can RWE be used to solve common challenges with treatment comparison? In...
Read More
Evelyne Priestman who recently joned our Health Economics Team, shares what inspired her to join Mtech Access and her experiences since joining the team
Calum Jones (Associate Director – Health Economics) shares his experience speaking at the 2024 HTAi Conference. Calum participated in the panel discussion: ‘Surrogate Endpoints in Health Technology Assessment (HTA): From Trials to Economic Evaluations’.
Hannah Palin (Director – Market Access) and Calum Jones (Associate Director – Health Economics) explore the landscape for economic evaluation in the US and highlight important considerations for companies seeking to infiltrate this key market.
We delve into ICER’s influence on drug pricing and access in the US. We also explore the importance of maximising engagement with ICER for favourable pricing and access outcomes.
Hayley Shoel shares her experience of joining Mtech Access’ specialist medical writing team. Explore the different types of projects she’s working on. Discover what you could expect if you joined us at Mtech Access.
Rachel Hibbs (Consultant – Systematic Review) tells us about her career to date and what inspired her to join Mtech Access.
We bring together specialists from across Mtech Access to look at each of ISPOR’s top 10 HEOR trends for 2024-25. Jump in, as our experts give their hot-take on each trend, sharing their perspectives on what’s happening in these areas.
What actions can you take in light of ISPOR’s top 10 HEOR trends? What impact may these issues have on your HEOR and Market Access strategy?
What is health economic evaluation and which modelling approaches can be used to support market access activities? In this webinar, our expert health economists explain the key strengths and limitations...
Read More
